CBRX News Alert Columbia Laboratories (CBRX) 5.58 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Columbia Laboratories (CBRX) 5.58 $CBRX

Molecular Profiles To Launch US Strategic Alliance At AAPS
PR Newswire - Thu Oct 30, 7:30AM CDT
Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) and Maryland-based Xceleron have announced a collaboration to assist drug developers with improved efficiency during clinical development that will be launched at AAPS in San Diego next week.
CBRX: 5.58 (+0.04)

Columbia Laboratories achieves higher Q3 2014 net income of USD3.7m
M2 - Wed Oct 29, 4:48AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) on Tuesday reported that its net income was USD3.7m, or USD0.34 per diluted share, for the three month periods ended 30 September 2014.
CBRX: 5.58 (+0.04)

Columbia Laboratories' (CBRX) CEO Frank Condella on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 1:39PM CDT

CBRX: 5.58 (+0.04)

Columbia Laboratories raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 1:05PM CDT

CBRX: 5.58 (+0.04)

Columbia Laboratories EPS of $0.34
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:18AM CDT

CBRX: 5.58 (+0.04)

Columbia Laboratories Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 28, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" today announced financial results for the three and nine-month periods ended September 30, 2014.
CBRX: 5.58 (+0.04)

OTC Daily Alert Stock Watch - Columbia Laboratories, Inc. (NASDAQ: CBRX)
WorldStockWire - Sun Oct 19, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CBRX: 5.58 (+0.04)

Columbia Labs reports on October 28
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 9:17AM CDT

CBRX: 5.58 (+0.04)

Columbia Laboratories to Discuss Third Quarter 2014 Financial Results on October 28th Conference Call
PR Newswire - Tue Oct 14, 11:51AM CDT
The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on October 28th, 2014, to discuss financial results for the third quarter ended September 30, 2014. The call details are as follows:
CBRX: 5.58 (+0.04)

Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI
PR Newswire - Wed Oct 01, 7:30AM CDT
Columbia Laboratories, Inc., (Nasdaq: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., is set to unveil the ROADMAP to Clinical Trials platform at the annual CPhI/ICSE Worldwide event in Paris next week, which aims to support companies with the rapid development of both standard and complex drug products.
CBRX: 5.58 (+0.04)

Columbia Laboratories announces George O. Elston as its new CFO
M2 - Thu Sep 25, 7:30AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) said on Wednesday that its board has appointed George O. Elston as its chief financial officer.
CBRX: 5.58 (+0.04)

Columbia Laboratories Announces Appointment of New Chief Financial Officer
PR Newswire - Wed Sep 24, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that the Board has named George O. Elston, 50, as Chief Financial Officer, effective October 1. He succeeds Jonathan Lloyd Jones, who is stepping down from the role to pursue other opportunities.
CBRX: 5.58 (+0.04)

Columbia Laboratories Shares Up 6.3% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - Mon Sep 22, 5:22PM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 14 months, Columbia Laboratories has returned 6.31% as of today's recent price of $5.98.
CBRX: 5.58 (+0.04)

Columbia Laboratories to participate in the Rodman & Renshaw 16th Annual Global Investment Conference
PR Newswire - Wed Aug 27, 8:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that it will participate at the upcoming Rodman & Renshaw 16th Annual Global Investment Conference, to be held in New York. The Company will present at the conference at 11:15am on September 9, 2014 at the New York Palace Hotel.
CBRX: 5.58 (+0.04)

Columbia Laboratories reports divestiture of Legatrin's IP and technology to Lil' Drug Store Products for USD2.2m
M2 - Thu Aug 07, 7:13AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) reported on Wednesday the sale of the Intellectual Property (IP) Rights and Technology related to Legatrin P.M to Lil' Drug Store Products following exercise of option from a previous agreement.
CBRX: 5.58 (+0.04)

Columbia Laboratories Announces Sale Of IP And Technology For Legatrin P.M. To Lil' Drug Store Products
PR Newswire - Wed Aug 06, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that Lil' Drug Store Products exercised its option to purchase the Intellectual Property Rights and Technology related to Legatrin P.M. Columbia licensed this product to Lil' Drug Store Products approximately fourteen years ago and has received annual royalties. Based on a predetermined formula, Columbia will receive approximately $2.2 million for the sale.
CBRX: 5.58 (+0.04)

Columbia Laboratories posts lower net income of USD0.2m for Q2 2014
M2 - Fri Aug 01, 8:16AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) stated on Thursday its net income of USD0.2m, or USD0.01 per diluted share, for the three month period ended 30 June 2014.
CBRX: 5.58 (+0.04)

Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis
PR Newswire - Thu Jul 31, 6:00AM CDT
Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., and XenoGesis Ltd., have announced a collaboration that will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage. Molecular Profiles' pharmaceutical development services will be supported by XenoGesis' expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound's bioavailability. This strategic alliance will allow the Nottingham-based companies to help drug developers in the initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies, as well as supporting lead candidates which have solubility issues during formulation development.
CBRX: 5.58 (+0.04)

Columbia Laboratories Reports Second Quarter 2014 Financial Results
PR Newswire - Thu Jul 31, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" today announced financial results for the three and six-month periods ended June 30, 2014.
MRK: 56.80 (-0.15), CBRX: 5.58 (+0.04)

Columbia Laboratories Up 11.8% Since SmarTrend Uptrend Call (CBRX)
Comtex SmarTrend(R) - Fri Jul 25, 9:59AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 12 months, Columbia Laboratories has returned 11.82% as of today's recent price of $6.29.
CBRX: 5.58 (+0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 140

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 203

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 95

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 126

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 78

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 116

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 172

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin Faces Criticism While BlackRock Sees Financial Success

Updated Category News Views 167

Bitcoin Under Scrutiny In recent discussions, Peter Schiff has taken to social media to share his critical views on Bitcoin, branding it as a "fake asset." His assertion comes after Bitcoin's price retracement from its historic highs, indicating a significant downturn. Currently, Bitcoin is trading at around $81,000 after once peaking at $110,000. Schiff argues that the...

Continue Reading
Valneva Secures $32.8 Million Contract for IXIARO Vaccine Supply

Updated Category News Views 213

Valneva Expands IXIARO Vaccine Supply with New Contract Valneva SE, a leading specialized vaccine company, has officially announced a significant step forward in its partnership with the U.S. Department of Defense (DoD) by signing a new contract valued at a minimum of $32.8 million for the IXIARO vaccine. This substantial agreement marks another chapter in Valneva's...

Continue Reading
EFGH and Minerva Forge Strategic Partnership for Data Centres

Updated Category News Views 118

EFGH and Minerva Unite to Enhance Ghana's Digital Landscape In a landmark agreement, Embed Financial Group Holdings (EFGH) has joined forces with Minerva Data Limited, a prominent player in digital infrastructure, to create advanced data centres and strengthen the technology ecosystem in Ghana. This collaboration marks a significant step in addressing the growing demand...

Continue Reading
Landsea Homes Achieves Remarkable Growth in Q3 Results

Updated Category News Views 50

Strong Financial Performance in Q3 Landsea Homes Corporation (NASDAQ: LSEA) reported impressive financial results for the third quarter, demonstrating robust performance in the residential homebuilding sector. For the quarter, Landsea Homes achieved a net income of $11.1 million, translating to $0.30 per share. This marks a 29% increase in net income compared to the...

Continue Reading
Urban Logistics REIT: Key Disclosure Insights for Investors

Updated Category News Views 219

Understanding the Disclosure from Urban Logistics REIT In the realm of public trading, disclosures play a pivotal role in keeping investors informed about changes in significant stakes within companies. Recently, Urban Logistics REIT Plc, underlining its commitment to transparency, provided valuable insights through its disclosure concerning investor positions, managed by...

Continue Reading